Shares of RegeneRx Biopharmaceuticals, Inc. (OTCMKTS:RGRX – Get Rating) dropped 9.2% on Friday . The company traded as low as $0.14 and last traded at $0.14. Approximately 1,641 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 37,085 shares. The stock had previously closed at $0.15.
RegeneRx Biopharmaceuticals Stock Down 9.2 %
The stock has a 50 day moving average of $0.15 and a two-hundred day moving average of $0.16.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.
- Get a free copy of the StockNews.com research report on RegeneRx Biopharmaceuticals (RGRX)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don’t Buy It Just Yet
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.